Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

The Lancet

Volumn 372, Issue 9634, 2008, Pages 216-223

  Holmes, Clive ^a,c   Boche, Delphine ^a   Wilkinson, David ^a,c   Yadegarfar, Ghasem ^b,e   Hopkins, Vivienne ^c   Bayer, Anthony ^f   Jones, Roy W ^g   Bullock, Roger ^h   Love, Seth ⁱ   Neal, James W ^f   Zotova, Elina ^a   Nicoll, James AR ^a,d  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c MOORGREEN HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^e ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f CARDIFF UNIVERSITY   (United Kingdom)

^g ROYAL UNITED HOSPITAL   (United Kingdom)

^h VICTORIA HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN[1-42];

AGED; ALZHEIMER DISEASE; ANTIBODY RESPONSE; ARTICLE; AUTOPSY; BRAIN CORTEX; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DISEASE SEVERITY; DRUG EFFECT; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; INFORMED CONSENT; KRUSKAL WALLIS TEST; MAJOR CLINICAL STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 47149112621     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61075-2     Document Type: Article

References (32)

1. Hardy J. Has the amyloid cascade hypothesis for Alzheimer's disease been proved?. Curr Alzheimer Res 3 (2006) 71-73
2. Schenk D., Barbour R., Dunn W., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (1999) 173-177
3. Bayer A., Bullock R., Jones R., et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 64 (2005) 94-101
4. Gilman S., Koller M., Black R., et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64 (2005) 1553-1562
5. Morgan D., Diamond D., Gottschall P., et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 (2000) 982-985
6. Nicoll J., Wilkinson D., Holmes C., Steart P., Markham H., and Weller R. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9 (2003) 448-452
7. Nicoll J., Barton E., Boche D., et al. Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol 65 (2006) 1040-1048
8. Bombois S., Maurage C., Gompel M., et al. Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia. Arch Neurol 64 (2007) 583-587
9. Orgogozo J.-M., Gilman S., Dartigues J.-F., et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61 (2003) 46-54
10. Hock C., Konietzko U., Streffer J., et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38 (2003) 547-554
11. Wilcock D., Jantzen P., Li Q., Morgan D., and Gordon M. Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience 144 (2007) 950-960
12. Pfeifer M., Boncristiano S., Bondolfi L., et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298 (2002) 1379
13. Smith M., Atwood C., Joseph J., and Perry G. Predicting the failure of amyloid-beta vaccine. Lancet 359 (2002) 1864-1865
14. Mattson M., and Chan S. Good and bad amyloid antibodies. Science 301 (2003) 26
15. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984) 939-944
16. Folstein M., Folstein S., and McHugh P. Mini mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975) 189-198
17. Rosen W., Mohs R., and Davis K. A new rating scale for Alzheimer's disease. Am J Psychiatry 141 (1984) 1356-1364
18. Gauthier S., Gelinas I., and Gauthier L. Functional disability in Alzheimer's disease. Int Psychogeriatr 9 suppl 1 (1997) 163-165
19. WHO. The ICD-10 classification of mental and behavioural disorders (1992), World Health Organisation, Geneva
20. Anon. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 18 4 suppl (1997) S1-S2
21. Lee M., Bard F., Johnson-Wood K., et al. Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann Neurol 58 (2005) 430-435
22. Davis D., Schmitt F., Wekstein D., and Markesbery W. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol 58 (1999) 376-388
23. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 357 (2001) 169-175
24. Engler H., Forsberg A., Almkvist O., et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 129 (2006) 2856-2866
25. Bacskai B., Kajdasz S., Christie R., et al. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 7 (2001) 369-372
26. Wilcock D., Rojiani A., Rosenthal A., et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 1 (2004) 24
27. Walsh D., Klyubin I., Fadeeva J., et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002) 535-539
28. Lesne S., Koh M., Kotilinek L., et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440 (2006) 352-357
29. Patton R., Kalback W., Esh C., et al. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol 169 (2006) 1048-1063
30. Weiner H., and Frenkel D. Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol 6 (2006) 404-416
31. Monsonego A., Zota V., Karni A., et al. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest 112 (2003) 415-422
32. Pride MW, Black RS, Hagen M, et al. Evaluation of potential immunologic mechanisms in the pathogenesis of treatment-induced meningoencephalitis in Alzheimer's disease patients treated with AN1792 (QS-21). International Conference on Alzheimer's Disease and Related Disorders; Philadelphia, PA, USA; July 17-22, 2004. P4-348.